FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015886911> ?p ?o ?g. }

• W3015886911 endingPage "1749" @default.
• W3015886911 startingPage "1744" @default.
• W3015886911 abstract "Background Patients treated with tumour necrosis factor (TNF) inhibitors are at risk of new-onset tuberculosis (TB) or reactivation of latent tuberculosis infection (LTBI). Association between TB/LTBI and interleukin (IL)-23 inhibitors for psoriasis is unclear. Patients with LTBI typically initiate LTBI therapy before receiving biologics. Objectives Safety in moderate-to-severe psoriasis patients with LTBI treated with guselkumab (IL-23 inhibitor) and LTBI treatment was evaluated. Methods In the VOYAGE 1 & VOYAGE 2 studies, patients screened for LTBI were randomized to guselkumab, placebo, or adalimumab (TNF inhibitor) at baseline. Placebo → guselkumab crossover occurred at week 16 and adalimumab → guselkumab at week 52 (VOYAGE 1), or at week 28 or later (VOYAGE 2). Incidence of active TB, adverse events (AEs), serious AEs (SAEs), and markedly abnormal liver function tests [alanine aminotransferase test (ALT); aspartate aminotransferase test (AST)] were evaluated using pooled data through week 100 in guselkumab-treated patients receiving and not receiving LTBI treatment. Results At baseline, 130 randomized patients (guselkumab: n = 69; adalimumab: n = 36; placebo: n = 25) tested positive for LTBI and received concomitant LTBI treatments (LTBI+). No active TB was reported among guselkumab-treated patients without LTBI (LTBI−) through week 100. Two cases of active TB occurred in LTBI− patients treated with adalimumab. Through week 16, across all treatment groups, greater proportions of LTBI+ patients reported ALT and AST elevations compared with LTBI− patients. Through week 100, proportions of patients experiencing AEs and SAEs were comparable between LTBI+ and LTBI− patients. Conclusions No cases of active TB, including reactivation of LTBI, were reported in patients with or without LTBI treated with guselkumab through up to 2 years. LTBI treatment was effective across all treatment groups in preventing reactivation of LTBI. Long-term treatment with guselkumab was generally well-tolerated through up to 2 years in patients receiving LTBI medications." @default.
• W3015886911 created "2020-04-17" @default.
• W3015886911 creator A5003311789 @default.
• W3015886911 creator A5006526834 @default.
• W3015886911 creator A5019115968 @default.
• W3015886911 creator A5027590834 @default.
• W3015886911 creator A5031300337 @default.
• W3015886911 creator A5035197780 @default.
• W3015886911 creator A5038505651 @default.
• W3015886911 creator A5058437940 @default.
• W3015886911 creator A5089128754 @default.
• W3015886911 date "2020-05-15" @default.
• W3015886911 modified "2023-09-29" @default.
• W3015886911 title "Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials" @default.
• W3015886911 cites W1777365448 @default.
• W3015886911 cites W1970496004 @default.
• W3015886911 cites W1980748590 @default.
• W3015886911 cites W2020976497 @default.
• W3015886911 cites W2071109139 @default.
• W3015886911 cites W2123228619 @default.
• W3015886911 cites W2180010286 @default.
• W3015886911 cites W2184272173 @default.
• W3015886911 cites W2570140560 @default.
• W3015886911 cites W2570141807 @default.
• W3015886911 cites W2602321146 @default.
• W3015886911 cites W2620710772 @default.
• W3015886911 cites W2748863627 @default.
• W3015886911 cites W2769106867 @default.
• W3015886911 cites W2941146433 @default.
• W3015886911 doi "https://doi.org/10.1111/jdv.16460" @default.
• W3015886911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32289190" @default.
• W3015886911 hasPublicationYear "2020" @default.
• W3015886911 type Work @default.
• W3015886911 sameAs 3015886911 @default.
• W3015886911 citedByCount "21" @default.
• W3015886911 countsByYear W30158869112020 @default.
• W3015886911 countsByYear W30158869112021 @default.
• W3015886911 countsByYear W30158869112022 @default.
• W3015886911 countsByYear W30158869112023 @default.
• W3015886911 crossrefType "journal-article" @default.
• W3015886911 hasAuthorship W3015886911A5003311789 @default.
• W3015886911 hasAuthorship W3015886911A5006526834 @default.
• W3015886911 hasAuthorship W3015886911A5019115968 @default.
• W3015886911 hasAuthorship W3015886911A5027590834 @default.
• W3015886911 hasAuthorship W3015886911A5031300337 @default.
• W3015886911 hasAuthorship W3015886911A5035197780 @default.
• W3015886911 hasAuthorship W3015886911A5038505651 @default.
• W3015886911 hasAuthorship W3015886911A5058437940 @default.
• W3015886911 hasAuthorship W3015886911A5089128754 @default.
• W3015886911 hasConcept C126322002 @default.
• W3015886911 hasConcept C142724271 @default.
• W3015886911 hasConcept C16005928 @default.
• W3015886911 hasConcept C17991360 @default.
• W3015886911 hasConcept C197934379 @default.
• W3015886911 hasConcept C204787440 @default.
• W3015886911 hasConcept C27081682 @default.
• W3015886911 hasConcept C2776967927 @default.
• W3015886911 hasConcept C2777975735 @default.
• W3015886911 hasConcept C2779384505 @default.
• W3015886911 hasConcept C2779806340 @default.
• W3015886911 hasConcept C2780132546 @default.
• W3015886911 hasConcept C2780564577 @default.
• W3015886911 hasConcept C2781069245 @default.
• W3015886911 hasConcept C71924100 @default.
• W3015886911 hasConceptScore W3015886911C126322002 @default.
• W3015886911 hasConceptScore W3015886911C142724271 @default.
• W3015886911 hasConceptScore W3015886911C16005928 @default.
• W3015886911 hasConceptScore W3015886911C17991360 @default.
• W3015886911 hasConceptScore W3015886911C197934379 @default.
• W3015886911 hasConceptScore W3015886911C204787440 @default.
• W3015886911 hasConceptScore W3015886911C27081682 @default.
• W3015886911 hasConceptScore W3015886911C2776967927 @default.
• W3015886911 hasConceptScore W3015886911C2777975735 @default.
• W3015886911 hasConceptScore W3015886911C2779384505 @default.
• W3015886911 hasConceptScore W3015886911C2779806340 @default.
• W3015886911 hasConceptScore W3015886911C2780132546 @default.
• W3015886911 hasConceptScore W3015886911C2780564577 @default.
• W3015886911 hasConceptScore W3015886911C2781069245 @default.
• W3015886911 hasConceptScore W3015886911C71924100 @default.
• W3015886911 hasFunder F4320337415 @default.
• W3015886911 hasIssue "8" @default.
• W3015886911 hasLocation W30158869111 @default.
• W3015886911 hasOpenAccess W3015886911 @default.
• W3015886911 hasPrimaryLocation W30158869111 @default.
• W3015886911 hasRelatedWork W1578809130 @default.
• W3015886911 hasRelatedWork W2131863130 @default.
• W3015886911 hasRelatedWork W2132509642 @default.
• W3015886911 hasRelatedWork W2399989376 @default.
• W3015886911 hasRelatedWork W2620100510 @default.
• W3015886911 hasRelatedWork W2622882429 @default.
• W3015886911 hasRelatedWork W2737526559 @default.
• W3015886911 hasRelatedWork W2910505523 @default.
• W3015886911 hasRelatedWork W4223569861 @default.
• W3015886911 hasRelatedWork W4295706067 @default.
• W3015886911 hasVolume "34" @default.
• W3015886911 isParatext "false" @default.
• W3015886911 isRetracted "false" @default.
• W3015886911 magId "3015886911" @default.

• next